
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2879978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Adjuvanted influenza vaccine for the Italian elderly in the 2018/19 season: an updated health technology assessment. European Journal of Public Health, 2019, 29, 900-905.	0.3	10
2	Heterogeneous estimates of influenza virus types A and B in the elderly: Results of a metaâ€regression analysis. Influenza and Other Respiratory Viruses, 2018, 12, 533-543.	3.4	15
3	One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine, 2018, 36, 381-387.	3.8	21
4	A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation. Human Vaccines and Immunotherapeutics, 2018, 14, 969-977.	3.3	15
5	Clustering of health-related behaviors among early and mid-adolescents in Tuscany: results from a representative cross-sectional study. Journal of Public Health, 2018, 40, e25-e33.	1.8	18
6	Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis. Vaccine, 2017, 35, 513-520.	3.8	184
7	Strategies and actions of multi-purpose health communication on vaccine preventable infectious diseases in order to increase vaccination coverage in the population: The ESCULAPIO project. Human Vaccines and Immunotherapeutics, 2017, 13, 369-375.	3.3	15
8	The role of age-sex interaction in the development of post-herpetic neuralgia. Human Vaccines and Immunotherapeutics, 2017, 13, 376-378.	3.3	10
9	Economic studies applied to vaccines against invasive diseases: An updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Human Vaccines and Immunotherapeutics, 2017, 13, 417-422.	3.3	6
10	Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine and Commonly Administered Vaccines After Coadministration. Pediatric Infectious Disease Journal, 2016, 35, 81-93.	2.0	20
11	Development and validation of the Italian version of the Mobile Application Rating Scale and its generalisability to apps targeting primary prevention. BMC Medical Informatics and Decision Making, 2016, 16, 83.	3.0	73
12	Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 2148-2161.	3.3	30
13	Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview. Human Vaccines and Immunotherapeutics, 2016, 12, 2616-2627.	3.3	37
14	Development and preliminary data on the use of a mobile app specifically designed to increase community awareness of invasive pneumococcal disease and its prevention. Human Vaccines and Immunotherapeutics, 2016, 12, 1080-1084.	3.3	20
15	An eHealth Project on Invasive Pneumococcal Disease: Comprehensive Evaluation of a Promotional Campaign. Journal of Medical Internet Research, 2016, 18, e316.	4.3	7
16	Trends in overweight and obesity prevalence in Tuscan schoolchildren (2002–2012). Public Health Nutrition, 2015, 18, 3078-3085.	2.2	17
17	Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	8
18	Porous Alumina as a Promising Biomaterial for Public Health. Advances in Protein Chemistry and Structural Biology, 2015, 101, 213-229.	2.3	9

#	Article	IF	CITATIONS
19	Quartz-Crystal Microbalance (QCM) for Public Health. Advances in Protein Chemistry and Structural Biology, 2015, 101, 149-211.	2.3	33
20	Assessing Ebola-related web search behaviour: insights and implications from an analytical study of Google Trends-based query volumes. Infectious Diseases of Poverty, 2015, 4, 54.	3.7	124
21	<i>Chlamydia trachomatis</i> prevalence and chlamydial/HPV co-infection among HPV-unvaccinated young Italian females with normal cytology. Human Vaccines and Immunotherapeutics, 2015, 11, 270-276.	3.3	20
22	Flucelvax (Optaflu) for seasonal influenza. Expert Review of Vaccines, 2015, 14, 789-804.	4.4	44
23	Human Papillomavirus Vaccine. Advances in Protein Chemistry and Structural Biology, 2015, 101, 231-322.	2.3	20
24	Human papillomavirus detection in paraffin-embedded colorectal cancer tissues. Journal of General Virology, 2015, 96, 206-209.	2.9	11
25	Age-Related Differences in the Accuracy of Web Query-Based Predictions of Influenza-Like Illness. PLoS ONE, 2015, 10, e0127754.	2.5	30
26	Uncontrolled Web-Based Administration of Surveys on Factual Health-Related Knowledge: A Randomized Study of Untimed Versus Timed Quizzing. Journal of Medical Internet Research, 2015, 17, e94.	4.3	8
27	The Impact of HPV Female Immunization in Italy: Model Based Predictions. PLoS ONE, 2014, 9, e91698.	2.5	8
28	Health Technology Assessment and vaccinations in Italy. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.2014.1236.	0.1	1
29	Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: Systematic review and meta-analysis. Human Vaccines and Immunotherapeutics, 2014, 10, 2819-2833.	3.3	38
30	Demand-based web surveillance of sexually transmitted infections in Russia. International Journal of Public Health, 2014, 59, 841-849.	2.3	7
31	<i>Neisseria meningitidis</i> B vaccines: recent advances and possible immunization policies. Expert Review of Vaccines, 2014, 13, 345-364.	4.4	22
32	Do the omeprazole family compounds exert a protective effect against influenza-like illness?. BMC Infectious Diseases, 2014, 14, 297.	2.9	5
33	Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years. Journal of Clinical Microbiology, 2014, 52, 1901-1910.	3.9	40
34	Prevalence of human papillomavirus in young Italian women with normal cytology: how should we adapt the national vaccination policy?. BMC Infectious Diseases, 2013, 13, 575.	2.9	17
35	Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines. Human Vaccines and Immunotherapeutics, 2013, 9, 1163-1171.	3.3	157
36	Influenza epidemiology in Italy two years after the 2009–2010 pandemic. Human Vaccines and Immunotherapeutics, 2013, 9, 561-567.	3.3	26

#	Article	IF	CITATIONS
37	Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy. Human Vaccines and Immunotherapeutics, 2013, 9, 699-706.	3.3	37
38	An overview of current and potential use of information and communication technologies for immunization promotion among adolescents. Human Vaccines and Immunotherapeutics, 2013, 9, 2634-2642.	3.3	30
39	Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V [®] and) Tj ETQq1 1 0.784314 rgBT Vaccines and Immunotherapeutics, 2013, 9, 144-152.	Overlock 3.3	10 Tf 50 60 42
40	Use of different subjective health indicators to assess health inequalities in an urban immigrant population in north-western Italy: a cross-sectional study. BMC Public Health, 2013, 13, 1006.	2.9	12
41	Detection and Genotyping of Human Papillomavirus in Urine Samples from Unvaccinated Male and Female Adolescents in Italy. PLoS ONE, 2013, 8, e79719.	2.5	11
42	Clinical and socioeconomic impact of seasonal and pandemic influenza in adults and the elderly. Human Vaccines and Immunotherapeutics, 2012, 8, 21-28.	3.3	101
43	Sexual behaviour and risk factors for the acquisition of human papillomavirus infections in young people in Italy: suggestions for future vaccination policies. BMC Public Health, 2012, 12, 623.	2.9	59
44	Can Particulate Air Sampling Predict Microbial Load in Operating Theatres for Arthroplasty?. PLoS ONE, 2012, 7, e52809.	2.5	51
45	Aflunov [®] : a prepandemic influenza vaccine. Expert Review of Vaccines, 2012, 11, 145-157.	4.4	21
46	<i>Neisseria meningitidis</i> B vaccines. Expert Review of Vaccines, 2011, 10, 1337-1351.	4.4	42
47	Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecologic Oncology, 2011, 121, 514-521.	1.4	24
48	Time Trade-Off Procedure for Measuring Health Utilities Loss With Human Papillomavirus–Induced Diseases: A Multicenter, Retrospective, Observational Pilot Study in Italy. Clinical Therapeutics, 2011, 33, 1084-1095.e4.	2.5	13
49	Burden of rotavirus infections in Liguria, northern Italy: hospitalisations and potential savings by vaccination. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 957-964.	2.9	12
50	Safety and tolerability of bivalent HPV vaccine: An Italian post-licensure study. Hum Vaccin, 2011, 7, 136-146.	2.4	17
51	Burden of the 1999-2008 seasonal influenza epidemics in Italy: Comparison with the H1N1v (A/California/07/09) pandemic. Hum Vaccin, 2011, 7, 217-225.	2.4	31
52	An overview on the implementation of HPV vaccination in Europe. Hum Vaccin, 2011, 7, 128-135.	2.4	43
53	Meningococcal glycoconjugate vaccines. Hum Vaccin, 2011, 7, 170-182.	2.4	55
54	Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetriaâ,,¢) in adult and elderly subjects. International Journal of Clinical Practice, 2010, 64, 432-438.	1.7	35

#	Article	IF	CITATIONS
55	A Heterologous MF59-Adjuvanted H5N1 Prepandemic Influenza Booster Vaccine Induces a Robust, Cross-Reactive Immune Response in Adults and the Elderly. Vaccine Journal, 2010, 17, 1817-1819.	3.1	32
56	Randomized Trial on the Safety, Tolerability, and Immunogenicity of MenACWY-CRM, an Investigational Quadrivalent Meningococcal Glycoconjugate Vaccine, Administered Concomitantly with a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis Vaccine in Adolescents and Young Adults. Vaccine Journal, 2010, 17, 537-544.	3.1	39
57	The health care burden and societal impact of acute otitis media in seven European countries: Results of an Internet survey. Vaccine, 2010, 28, G39-G52.	3.8	61
58	MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults. PLoS ONE, 2009, 4, e4384.	2.5	165
59	Sexual behaviour in Ligurian (Northern Italy) adolescents and young people: Suggestions for HPV vaccination policies. Vaccine, 2009, 27, A6-A10.	3.8	14
60	On the relationship between meningococcal transmission dynamics and disease: Remarks on humoral immunity. Vaccine, 2009, 27, 3429-3434.	3.8	15
61	Preface. Vaccine, 2009, 27, A1.	3.8	2
62	Human papillomavirus vaccination: what is the best choice? A comparison of 16 strategies by means of a decisional model. Epidemiology and Infection, 2009, 137, 794-802.	2.1	4
63	Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. European Journal of Epidemiology, 2008, 23, 45-53.	5.7	23
64	Cross-protection by MF59â,,¢-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine, 2008, 26, 1525-1529.	3.8	117
65	Safety and Immunogenicity of Two Influenza Virus Subunit Vaccines, with or without MF59 Adjuvant, Administered to Human Immunodeficiency Virus Type 1-Seropositive and -Seronegative Adults. Vaccine Journal, 2008, 15, 253-259.	3.1	64
66	Burden of Rotavirus-Associated and Non-Rotavirus-Associated Diarrhea among Nonhospitalized Individuals in Central Italy: A 1-Year Sentinel-Based Epidemiological and Virological Surveillance. Clinical Infectious Diseases, 2008, 46, e51-e55.	5.8	10
67	Molecular Characterization of a New Variant of Rotavirus P[8]G9 Predominant in a Sentinel-Based Survey in Central Italy. Journal of Clinical Microbiology, 2007, 45, 1011-1015.	3.9	19
68	The Cost-Effectiveness of Influenza Vaccination for People Aged 50 to 64 Years: An International Model. Value in Health, 2007, 10, 98-116.	0.3	60
69	Long-term decline of 137Cs concentration in honey in the second decade after the Chernobyl accident. Science of the Total Environment, 2007, 382, 147-152.	8.0	8
70	Influenza and respiratory syncytial virus in infants and children: relationship with attendance at a paediatric emergency unit and characteristics of the circulating strains. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 619-628.	2.9	13
71	Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. Journal of Viral Hepatitis, 2006, 13, 5-10.	2.0	32
72	Neutralizing and Hemagglutination-Inhibiting Activities of Antibodies Elicited by the 2004-2005 Influenza Vaccine against Drifted Viruses. Vaccine Journal, 2006, 13, 162-164.	3.1	12

#	Article	IF	CITATIONS
73	Clinical and socio–economic impact of influenza and respiratory syncytial virus infection on healthy children and their households. Clinical Microbiology and Infection, 2005, 11, 933-936.	6.0	49
74	Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. Journal of Medical Virology, 2005, 76, 327-332.	5.0	153
75	New A/H3N2 Influenza Variant: a Small Genetic Evolution but a Heavy Burden on the Italian Population during the 2004-2005 Season. Journal of Clinical Microbiology, 2005, 43, 3027-3029.	3.9	24
76	Epidemiological trend in tuberculosis in the Italian region of Liguria: Impact of immigration and AIDS. European Journal of Public Health, 2005, 15, 339-342.	0.3	12
77	Burden of influenza in healthy children and their households. Archives of Disease in Childhood, 2004, 89, 1002-1007.	1.9	96
78	Antigenic characterisation of influenza B virus with A new microneutralisation assay: Comparison to haemagglutination and sequence analysis. Journal of Medical Virology, 2004, 74, 141-146.	5.0	16
79	The impact of influenza and respiratory syncytial virus in a 0–14-year children cohort: a comparison with the national network and between methods for influenza virological surveillance. International Congress Series, 2004, 1263, 329-333.	0.2	1
80	High heterogeneity of influenza B viruses circulating in Northern Italy during the 2001/2002 and 2002/2003 seasons. International Congress Series, 2004, 1263, 321-324.	0.2	0
81	Surveillance of influenza in Apulia, Italy, 1999–2000, 2000–2001, 2001–2002, and 2002–2003 seasons. Médecine Et Maladies Infectieuses, 2004, 34, 469-476.	5.0	6
82	Influenza Vaccination. Zeitschrift Fur Gesundheitswissenschaften, 2003, 11, 221.	1.6	0
83	Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season. Journal of Medical Virology, 2003, 70, 463-469.	5.0	39
84	Valutazione benefici-costi della vaccinazione antinfluenzale negli anziani in Liguria. Pharmacoeconomics Italian Research Articles, 2003, 5, 23-30.	0.2	5
85	Seroprevalence of HTLV-I and HTLV-II infection among immigrants in northern Italy. European Journal of Epidemiology, 2002, 18, 583-588.	5.7	6
86	Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. European Journal of Epidemiology, 2001, 17, 135-140.	5.7	105
87	Chlamydia pneumoniae antibodies and angiographically demonstrated coronary artery disease in a sample population from Italy. Atherosclerosis, 1999, 145, 81-85.	0.8	15
88	Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatric Infectious Disease Journal, 1999, 18, 677-682.	2.0	23
89	Immunity to diphtheria in Siena. Epidemiology and Infection, 1997, 119, 203-208.	2.1	10
90	Evaluation of in vitro efficacy of the disinfectant Virkon. European Journal of Epidemiology, 1995, 11, 193-197.	5.7	50

#	Article	IF	CITATIONS
91	Prevalence of streptococcus mutans and dental decay in school children from Siena (Italy). European Journal of Epidemiology, 1989, 5, 189-192.	5.7	9